First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …

K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - jamanetwork.com
Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
被引用次数：259 相关文章

First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …

K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - pure.lib.cgu.edu.tw
Importance: Continuing molecularly targeted treatment beyond disease progression in non-
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …

K Park, CJ Yu, SW Kim, MC Lin… - JAMA …, 2016 - cuk.elsevierpure.com
Importance: Continuing molecularly targeted treatment beyond disease progression in non-
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor …

CJ Yu, SW Kim, MC Lin, CM Tsai, JS Lee… - JAMA …, 2016 - scholarworks.bwise.kr
IMPORTANCE Continuing molecularly targeted treatment beyond disease progression in
non-small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …

K Park, CJ Yu, SW Kim, MC Lin… - JAMA …, 2016 - mdanderson.elsevierpure.com
Importance: Continuing molecularly targeted treatment beyond disease progression in non-
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor …

K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - europepmc.org
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors
Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive …

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor …

K Park, CJ Yu, SW Kim, MC Lin… - JAMA …, 2016 - pubmed.ncbi.nlm.nih.gov
Importance Continuing molecularly targeted treatment beyond disease progression in non-
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …

K Park, CJ Yu, SW Kim, MC Lin… - JAMA …, 2016 - snucm.elsevierpure.com
Importance: Continuing molecularly targeted treatment beyond disease progression in non-
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

[引用][C] First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor …

K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA Oncology, 2016 - cir.nii.ac.jp
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors
Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive …
[PDF] academia.edu

[PDF][PDF] First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor …

K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA, 2016 - academia.edu
OBJECTIVE To study the efficacy of first-line erlotinib therapy in patients with NSCLC with
activating EGFR mutations and postprogression erlotinib therapy. DESIGN, SETTING, AND …